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Introduction
Large randomized clinical trials have demonstrated that implantable cardioverter-defibrillator (ICD) therapy improves survival in patients at risk for life-threatening ventricular arrhythmias. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Due to the expanded indications for ICD therapy, the number of implantations on account of a primary prevention indication has increased. [11] [12] [13] [14] [19] [20] [21] It is expected that primary prevention patients will survive their ICD service time, and so will need one or more replacements. For several reasons, as patients' comfort, risk and cost control, there is no doubt to strive for keeping the number of replacements as low as possible. Therefore, device longevity is an important parameter in the choice of a specific device or device system for each individual case. In the last decade, ICD technology has advanced into complex arrhythmia management systems, with comprehensive diagnostic tools. In parallel, battery and lead technology have also improved. Device longevity as provided by the manufacturers is usually based on intensive testing under ideal standardized and conditioned laboratory measurements. In contrast, one may assume that device longevity could be different in clinical situations. About ICD longevity under clinical circumstances, there is little information available. Therefore, the purpose of the study was to investigate ICD service time under clinical circumstances, and whether a relation could be found with some theoretical longevity-influencing parameters.
Methods

Study Population
The study population consisted of 854 consecutive patients who received a first ICD implantation between October 1998 and December 2006 at Erasmus Medical Center, Rotterdam, the Netherlands. Baseline characteristics of the study population and characteristics of the implanted ICD system were collected. The baseline characteristics consisted of demographic data, indication for ICD therapy, cardiac function and functional class, underlying cardiac disease, and pharmacological therapy. Regarding the implanted system, data were collected on the manufacturer, device model, and the type of the ICD; whether it was a single-chamber (SC), dual-chamber (DC) or a defibrillator incorporated with cardiac resynchronization therapy (CRT-D).
Indications for Replacement
All replacement procedures within the study population were analyzed with respect to the indication for device replacement. Indications for device replacement were divided into a normal end of service (EOS) premature EOS, infection, device advisory or recall, and system malfunction. Device advisory or recall was defined as a manufacturer initiated recommendation for ICD replacement. Premature EOS was defined as an EOS within 36 months after implantation, which is based on the common value given in the warranties provided by the diverse manufacturers. All other replacements after more than 36 months service time were defined as normal EOS. A system malfunction included a malfunction of the pulsegenerator, the header, or at least one of the implanted leads. In addition, insufficient energy capacity for successful defibrillation threshold (DFT) testing was defined as a system malfunction.
ICD Bradycardia and Tachycardia Settings
Cardiac stimulation parameters, in general, were set to low-rate backup pacing modes in SC ICDs, except in patients with an indication for stimulation or rate regulation. In general, DC ICDs were programmed in a nontracking backup mode DDI, to avoid unnecessary right ventricular (RV) pacing, except for those patients, where stimulation was indicated. All CRT-D ICDs were programmed to achieve maximal biventricular (BiV) stimulation. The lower rate was programmed in favor of the patients' natural sinus rhythm, to minimize atrial stimulation. The majority of devices were programmed in a dual-zone configuration for arrhythmia detection (74%). The programmed rate cut-offs of the fibrillation and tachycardia zones were 289 ± 15 ms and 370 ± 43 ms, respectively. Available discriminators were immediately activated after ICD implantation to avoid inappropriate ICD therapy for atrial tachyarrhythmias.
Device Longevity
To determine the influence of clinical circumstances on ICD longevity, data on bradycardia and tachycardia parameters were collected from saved regular follow-ups and lifetime ICD holters. Bradycardia parameters included the programmed pacing mode, rate cut-off values (at time of implantation), the number and the lifetime percentage of stimulated channels, the presence of high output (HO) stimulation, and the presence of active rate-responsive (RR) settings. HO stimulation was arbitrarily defined as more than 50% stimulation on at least one channel, with at least an output of 3.5 V voltage and 0.4 ms pulse width. For tachycardia therapy history data, the number of delivered HV shocks and the number of automatic capacitor reformations, as far as possible, were collected.
Data Analysis
All patients were followed at 3-to 6-month intervals after the last operation procedure. For the analysis of longevity, only replacements indicated by a device-based EOS message (premature EOS and normal EOS) were used. The exclusion criteria for longevity analysis were replacements indicated by an infection, a device advisory or recall, or a system malfunction, as these events led to prompt corrective and preventive actions. Longevity was calculated as the time span between implantation and replacement (months), and was compared for SC, DC, and CRT-D systems, for systems with HO stimulation versus systems without HO stimulation and for systems with or without active RR settings. Longevity was also compared among different manufacturers. test was used for analysis of categorical data. The Kaplan-Meier method was used to calculate actuarial event-free rates from a device replacement, and differences were compared with log-rank testing. A P-value < 0.05 was considered statistically significant.
Results
Study Population
During Categorical data are presented as n, (%). ACE = angiotensin-converting enzyme; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CHF = congestive heart failure; DCM = dilated cardio-myopathy; HCM = hypertrophic cardio-myopathy; LVEF = left ventricle ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association.
data of these patients are presented in Table I . The majority of the patients were male (78.9%), had documented coronary artery disease (62.4%), and a reduced left ventricular function. Primary prevention indication for ICD therapy was present in 42.8% of the patients. In the same time period, 165 of these patients (19.3%) underwent a total of 203 ICD generator replacements: a total of 127 patients (14.9%) underwent one replacement, 33 patients (3.9%) underwent two replacements, and even three replacement procedures were performed in five patients (0.6%). Primary prevention indication was present in 44 patients (26.7%), who underwent a generator replacement.
The numbers and models of the ICDs, involved in the study, are summarized in Table II , as well as the manufacturers' warranty and the battery specifications.
Indications for a Replacement
Between October 1998 and December 2006, a total of 1,057 implant procedures were performed in our institute. Of these, 854 were first ICD implantations, and 203 were replacements. The indications for a device replacement are presented in Table III . After the first implantation, infection occurred in seven patients (7/854 = 0.8%) of the study population. In addition, three infections were observed after replacement (3/203 = 1.4%). This total of 10 infections resulted in a system replacement and contributed for 4.9% as an indication for a replacement. Device advisory or recall was the indication for a replacement of 30 ICDs (14.8%). From the 203 ICD replacements, nine (4.4%) were due to a system malfunction, including three replacements (1.5%) due to insufficient energy capacity for successful DFT testing. A premature EOS, excluding device advisory or recall, was present in 59 ICDs (29.1%), and a normal EOS was present in 95 ICDs (46.8%).
Distribution of Clinical Variables
The cohort for longevity analysis consisted of replacements on account of a premature and a normal EOS, which represented a total of 154 replacements. Of these, 32 were SC (20.8%), 98 were DC (63.6%), and 24 were CRT-D (15.6%). Table IV summarizes the distribution of pacing percentage, the number and percentage of HO stimulation and active RR settings, and the median number of HV therapies among the replaced devices. The mean percentage of pacing was lower for SC devices (14%) and higher for CRT-D (atrial 21%, ventricular 98%). The percentage of HO stimulation was significantly higher in CRT-D devices compared to SC and DC devices (54% vs. 25% and 38%, respectively; P = 0.02). RR pacing settings were activated only in a minority of the replaced devices. The proportion of active RR pacing settings was higher in SC devices compared to DC and CRT-D devices (13% vs. 5% and 8%, respectively), although statistically this was not significant. There was also no significant difference in the number of HV therapies between SC, DC, and CRT-D devices. In addition, no significant differences in HO stimulation, active RR settings, and median number of HV therapies were found among the different manufacturers between SC, DC, and CRT-D.
Device Longevity
Longevity data are shown in Figure 1 . The mean longevity of SC devices was significantly longer compared to DC and CRT-D devices (53.7 ± 19.0 months vs. 40.0 ± 16.9 and 42.2 ± 14.5 months, respectively, P = 0.008). There was no significant difference in longevity between DC and CRT-D devices. The actuarial event-free rates for a replacement of SC, DC, and CRT-D are presented in Figure 2 , which confirmed the previous calculations. No difference in longevity was observed between devices with an active RR setting and devices without an RR setting (44.9 ± 13.4 months vs. 43.1 ± 18.2 months), however an active RR pacing setting was only programmed in 11 of 203 devices (7.1%). A similar result was 4 months for GDT, 30.7 ± 9.5 months for SJM). Actuarial event-free rates from a device replacement are presented in Figure 3 . Devices manufactured by BIO had lower actuarial event-free rates from a device replacement compared with MDT devices (99.5%, 90.7%, and 10% vs. 99.5%, 99.5%, and 88.2%, at 1, 2, and 5 years, respectively; P < 0.001). ELA, Guidant, and St. Jude had an intermediate position.
Figure 2. Event-free survival for single-chamber (SC), dual-chamber (DC), and cardiac resynchronization therapy-defibrillator (CRT-D) devices.
Discussion
The major findings of this study were that SC devices have a significantly longer service time, compared to DC or CRT-D devices. In this study, PACE, Vol. 32 KNOPS, ET AL. longevity was not significantly affected by active RR settings and pacing with HO. In addition, no difference was found in longevity between ICDs implanted on indication of a primary or secondary prevention profile. Between manufacturers, the longest service time was provided by ICDs from Medtronic.
Primary Versus Secondary Prevention
In the last decade, several large randomized clinical trials have clarified that prophylactic ICD implantation in patients at risk for life-threatening ventricular tachy-arrhythmias, is more effective in the prevention from sudden cardiac death (SCD) than commonly used pharmacological treatment. [5] [6] [7] [8] [9] [10] Due to these trials, the international guidelines for ICD implantation have expanded. [11] [12] [13] The guidelines have also included some specific and well-studied structural heart diseases and ion-channel abnormalities. [14] [15] [16] [17] Today, the majority of ICDs are implanted on account of a prophylactic indication. 18, 19 The majority of these primary prevention patients is expected to survive their first ICD and therefore will need one or more device replacements. 20 Patients themselves, tend to prefer a longer device service time above, for example, device dimensions. 21 Device longevity thus has become an important device characteristic value. We showed in this study that secondary prevention was not associated with shorter device longevity.
Indications for Stimulation
ICD recipients, indicated for prophylactic ICD implantation, commonly do not exhibit any need for (atrioventricular synchronous) cardiac stimulation against bradycardia. 22, 23 Even if ICD therapy is combined with drug therapy such as β-blockers, it has been shown that SC (low rate backup stimulation) is preferable over DC stimulation in these patients. [24] [25] [26] In the last decade, several authors also showed, that addition of an atrial lead for arrhythmia discrimination is not necessary to avoid an inappropriate therapy, [27] [28] [29] [30] [31] and even can have adverse effects. [32] [33] [34] So, only in patients, who have significant sinoatrial or atrioventricular rhythm disturbances, the implantation of a DC ICD seems justified. The CRT-D is only indicated for heart failure patients, who meet the criteria for resynchronization therapy and who have an increased risk for arrhythmic death. These patients benefit from bifocal ventricular stimulation, as studies demonstrated. [35] [36] [37] [38] Possible reasons for the unequal distribution of the percentage of pacing, HO stimulation, and active RR settings between SC, DC, and CRT-D systems, could be the difference in the implanted system and preferred programming. However, no significantly different distribution of these variables among manufacturers could be noticed between the SC, DC, and CRT-D groups. We found that DC and CRT-D devices were associated with higher percentages of stimulation (with or without HO) and lower percentage of active RR pacing. In combination, these factors seem to adversely influence longevity. In contrast, an adverse effect of only HO stimulation or RR pacing on device longevity was not found in this study.
ICD Battery Technology and Longevity
ICD battery technology has shown a continuing improvement over time. The results are today's different types of small power sources, of different materials, with different imposing electrical properties and battery capacity. The majority of the power sources for ICDs are composed of a lithium (Li) anode and a cathode of silver vanadium oxide (SVO). The two main differences in cathode technology are the different doses of the individual elements and the different (thermo-chemical) manufacturing process of the SVO compound. Today, this has resulted in a large variety of different SVO cathodes for application in small powerful (ICD) batteries. The latest developments in battery cathode technology are the addition of carbon monofluoride (CFx)/SVO, CFx alone, a metal oxide, for instance manganese dioxide (MnO 2 ), or combinations of these materials. It is believed, this technology will improve the battery power capability. A large variety of factors have their impact on the discharge characteristics of these batteries. A limitation of manufacturer's predicted ICD longevity is that this value is commonly calculated under generalized laboratory settings with very specific bradycardia settings, without RR or HO stimulation settings and limited and regularly distributed HV discharges. This is not what tends to happen under clinical circumstances. For this reason, a simple comparison between ICD battery type and ICD longevity can not be drawn. For example, each of the following factors are all of importance during battery discharge: current consuming of the ICDs electrical circuit, increased diagnostic functions and remote monitoring tools, capacitor characteristics, lead developments to steroid-eluting leads with different current drawn, IEGM (pre)storage functions, the need of individual device programming for each individual patient, and the battery capacity of the ICD itself. Of course, this summary is not complete. By manufacturers, effective battery capacity is considered to be confidential and is mostly not provided. For ICDs involved in this study, the longest service time was exhibited by MDT devices. Ever since the Marquis platform and in contrast to other manufacturers, MDT has manufactured and has used batteries with a thermally different produced SVO crystal structure. This is the so-called "combination" SVO (CSVO). CSVO makes the batteries more stable. 39 Li/SVO batteries based on CSVO show obvious differences in the crystal morphology and degree of crystallinity, and exhibit a lower rate of time-dependent permanent resistance increase. 40 These factors result in a more stable and better battery performance, which could be translated in a better device performance. 41 For as far as the battery capacity was provided or could be retrieved, MDT ICD batteries showed a greater capacity (>1.1 Ah) when compared to batteries used by other manufacturers. ICDs of BIO in this study, demonstrated the shortest longevity. First of all, also here, it seems that a direct relation with the battery capacity can be noticed. As far as known, involved BIO ICD batteries, showed the smallest capacity (0.6-0.9 Ah). Second, of the investigated ICDs, only BIO batteries are made of LiMnO 2 instead of Li/SVO. And finally, some ICD types of BIO are fitted with separated batteries for lowvoltage and high-voltage therapy. ELA battery capacity amounted 1.0 Ah and ELA devices showed an intermediate longevity. No battery capacity was provided for GDT and SJM devices. Therefore, their battery capacity could not be compared to other manufacturers.
Limitations
This study had some limitations. First, a complete in-depth analysis on the distribution of the clinical variables in relation to different manufacturers or different device models was not performed. Although a compact overview per manufacturer, per device type is presented in Table IV , the numbers for each particular manufacturer or device model are too low. Clinical variables also can be unequally distributed. For instance, the percent of pacing and the number of HV discharges can be affected by numerous factors, such as different etiology of a cardiac disease, the indication for ICD therapy, presence of electrical storms, selected device type, distribution of different ICD systems between manufacturers, etc. In addition, during service time the interval for battery and capacitor maintenance varied between 3 and 6 months among different manufacturers, and depended on battery voltage as an indicator of battery performance. These charges were not counted within the calculated average number of HV therapies, but have an effect on longevity. Second, the choice for specific manufacturers and device models was not random, but determined by annual agreements between the hospital administration and the different manufacturers. Third, only a minor part of the replaced ICDs was programmed with an active RR sensor setting. No conclusions about the influence of RR settings on longevity could be drawn PACE, Vol. 32 from this study data. Another limitation was, that the defined value, whether an output had to be considered as HO stimulation or not, was arbitrarily chosen. Battery drainage is, besides voltage, dependent on multiple other factors, such as lead impedance, current drawn, and stimulation frequency.
During the study, a voluntary recall had a significant impact on the cohort of patients with BIO devices, supplied with the battery type LiS 3482. Due to the formation of a passivation layer at the battery anode, battery impedance increased too fast and extended capacitor charge time. 42 This resulted in an interruption of capacitor charging and a triggering of EOS indication. After intensified testing, the affected ICDs were scheduled for a replacement, and thus excluded from a longevity analysis. The nonaffected ICDs with the same battery type were automatically reprogrammed to an intensive internal battery impedance monitoring protocol by a modified programmer software. In cases the regularly checked battery charge time started to increase too fast, intensified battery charges, to prevent the build-up of a passivation layer, were performed. This intensified battery maintenance may significantly decrease the longevity of these devices. These devices could be followed up until an EOS message from the device occurred. Due to the chosen definitions, these devices were involved in the longevity analysis. Without this extreme capacitor maintenance, it is likely that longevity of these devices, and the average longevity of BIO ICDs would have been higher. On the other hand, we were lucky to have no devices affected from recalls of other manufacturers, which might have influenced the outcome in another direction. Until today, all other ICDs within the study population have not shown abnormal battery behavior, and were not affected by possible malfunctions, as have been described in other advisories. Unfortunately, studies such as these are always outdated: The results of today are based on the technology of past years, and does not predict anything regarding longevity of new ICD releases, with an improved battery technology.
Recommendations
The authors are of opinion that the significantly longer service time of SC ICDs, demonstrated in this study, in combination with previously mentioned results of publications, are strong arguments for the implantation of SC ICDs in primary prevention patients without sinoatrial and atrioventricular conduction disturbances. With the status of current available ICD technology, the implantation of a DC ICD system, with or without CRT seems only justified when atrial or synchronized (bi)ventricular stimulation is needed. The ongoing development of new ICD technology and the implementation of new ICD power sources forces and challenges us to continue the investigation on clinical ICD longevity in today's and future ICDs.
